Diese Studie enthält eine ausreichend große Teilnehmerzahl. Sie können sich hierfür nicht mehr an- oder abmelden.

Knochenkrankheiten

Ort der Studie

  • Geschlecht Beides
  • Alter von 22 bis 65
  • Gewicht in kg von 50 bis 110
  • Rauchgewohnheiten maximal 5 pro Tag
  • BMI von 18 bis 30
  • Berechnen Sie Ihren BMI hier

Knochenkrankheiten
Clinical trial of a new compound that is being developed for the treatment of bone diseases

 

The research physician about this research

In this trial, it is examined how safe the new compound is and how well it is tolerated if it is used by healthy participants. It is also being investigated how quickly and to what extent the new compound is absorbed and excreted by the body. The compound will be tested in different strengths.

Für Deutschland: Bitte beachten Sie: Die Arzneimittelstudien finden im niederländischen Groningen statt. Sie müssen Englisch oder Niederländisch sprechen, verstehen und lesen können, um an einer Studie teilnehmen zu können. 

Important information about this study

  • In part 1 of the study, the study compound is administered once.
  • As a smoker you can also participate in this medical trial.
  • You will contribute significantly to the development of medications for people with bone diseases. For example, in the treatment of bone fracture healing.

 

Group B2

2 × 3 Tage, 7 Tage und 12 Tage Aufenthalt
16 Jan 2024 bis einschl. 27 Jan 2024
30 Jan 2024 bis einschl. 1 Feb 2024
6 Feb 2024 bis einschl. 8 Feb 2024
13 Feb 2024 bis einschl. 19 Feb 2024

kurzer Besuch
3 Feb 2024
10 Feb 2024
21 Feb 2024
28 Feb 2024
6 Mär 2024
13 Mär 2024
20 Mär 2024
27 Mär 2024
3 Apr 2024

Nachuntersuchung
10 Apr 2024

€ 8.414

 

Who can participate?

  • You are a healthy male or female.
  • You are between 22 and 65 years old.
  • Your weight is at least 50.0 kg and at most 110.0 kg and your Body Mass Index (BMI) is between 18.0 and 30.0 kg/m2. 
  • Both non-smokers and light smokers or occasional smokers are allowed to participate in this clinical trial (at most 5 cigarettes daily). During your stay in our research facility you are not allowed to smoke.

Note: 

  • You cannot participate in the trial if you have participated in another clinical trial in the 30 days prior to the first compound administration in this clinical trial (counting from the follow-up).
  • To determine if you are suitable to participate in this trial, you will undergo a medical screening. Depending on availability, this can be performed in Groningen or in Utrecht. 

As a female you can only participate if you are not pregnant, not breast feeding and meet one of the following conditions:

  • You are using continuous hormonal contraception (the pill or a hormonal IUD) in combination with a condom, cervical cap, or diaphragm used by your male partner;
  • You have passed the menopause (no periods for at least 12 months);
  • You have been sterilized (ovariectomy).

As a male you can only participate if you meet one of the following conditions:

  • You are using a condom in combination with an additional contraception method used by your female partner;
  • You have been sterilized or your female partner is sterilized or has passed the menopause (no periods for at least 12 months);
  • You are not sexually active according to your lifestyle;
  • You are only sexually active with a partner of the same sex.

 

Compensation

  • You will receive a gross compensation of € 3916 for participation in one of the groups of part A. F

Travel expenses will be reimbursed based on the distance traveled (€ 0.21 net per kilometer) with a minimum of € 13 and a maximum of € 176.40 (840 kilometers) per round trip, regardless of the mode of transportation.

 

Period of stay and research

  • Part A: The trial consists of 1 period during which you will stay in the research facility in Groningen (location van Swietenlaan 6) for 9 days (8 nights), followed by 8 short visits. The follow-up will be during the final short visit.

Note: You must be available for all dates to be able to participate in this clinical trial. 

link2trials

© 2025 Link2Trials